Related Experiment Videos
Dexclamol, a candidate for neuroleptanalgesia
Canadian Journal of Physiology and Pharmacology
|April 1, 1976
Summary
Dexclamol, a neuroleptic, enhances halothane anesthesia in rats, similar to droperidol. Phenoperidine further boosted this effect. Dexclamol showed less potency against epinephrine's vasopressor actions compared to droperidol.
Area of Science:
- Pharmacology
- Anesthesiology
- Neuroscience
Background:
- Neuroleptics can modulate anesthetic effects.
- Halothane is a commonly used inhalation anesthetic.
- Droperidol serves as a benchmark for neuroleptic activity.
Purpose of the Study:
- To investigate the anesthetic-potentiating effects of dexclamol.
- To compare dexclamol's effects with droperidol.
- To assess the influence of phenoperidine on dexclamol-halothane interactions.
Main Methods:
- Administration of dexclamol and phenoperidine to albino rats.
- Evaluation of anesthetic potentiation of halothane.
- Comparison with droperidol as a standard.
- Assessment of antagonism against epinephrine-induced vasopressor effects.
Main Results:
- Dexclamol potentiated halothane anesthesia in a manner qualitatively and quantitatively similar to droperidol.
- Phenoperidine enhanced the anesthetic effects of dexclamol-halothane combination.
- Dexclamol was significantly less potent (37 times) than droperidol in antagonizing epinephrine's vasopressor effects.
Conclusions:
- Dexclamol exhibits significant anesthetic-potentiating properties, comparable to droperidol.
- The combination of dexclamol and phenoperidine offers enhanced anesthetic effects.
- Dexclamol possesses a different pharmacological profile than droperidol regarding cardiovascular effects.